EBSEmergent BioSolutions Inc.

NYSE emergentbiosolutions.com


$ 7.91 $ 0.01 (0.13 %)    

Friday, 13-Sep-2024 13:11:39 EDT
QQQ $ 475.86 $ 2.43 (0.51 %)
DIA $ 415.32 $ 2.69 (0.65 %)
SPY $ 562.48 $ 2.21 (0.39 %)
TLT $ 100.51 $ 0.03 (0.03 %)
GLD $ 238.69 $ 1.10 (0.46 %)
$ 7.63
$ 7.90
$ 7.91 x 100
$ 7.94 x 100
$ 7.82 - $ 8.16
$ 1.42 - $ 15.10
943,512
na
403.68M
$ 1.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-01-2024 03-31-2024 10-Q
3 03-08-2024 12-31-2023 10-K
4 12-11-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-01-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-01-2022 06-30-2022 10-Q
10 04-28-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 11-05-2021 09-30-2021 10-Q
13 07-30-2021 06-30-2021 10-Q
14 04-30-2021 03-31-2021 10-Q
15 02-19-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 07-31-2020 06-30-2020 10-Q
18 05-01-2020 03-31-2020 10-Q
19 02-25-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-02-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 02-22-2019 12-31-2018 10-K
24 11-02-2018 09-30-2018 10-Q
25 08-03-2018 06-30-2018 10-Q
26 05-04-2018 03-31-2018 10-Q
27 02-23-2018 12-31-2017 10-K
28 11-03-2017 09-30-2017 10-Q
29 08-04-2017 06-30-2017 10-Q
30 05-05-2017 03-31-2017 10-Q
31 02-28-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-05-2016 06-30-2016 10-Q
34 05-06-2016 03-31-2016 10-Q
35 02-29-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-06-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 03-06-2015 12-31-2014 10-K
40 11-10-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rodman--renshaw-reiterates-buy-on-emergent-biosolutions-maintains-16-price-target

Rodman & Renshaw analyst Brandon Folkes reiterates Emergent BioSolutions (NYSE:EBS) with a Buy and maintains $16 price t...

Core News & Articles

- Reuters Citing State TV

 emergent-biosolutions-awarded-rd-option-valued-at-419m-for-continued-advanced-development-and-procurement-of-ebanga-treatment-for-ebola

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it was awarded a contract modification executing an option period by...

Core News & Articles

 - Reuters

Core News & Articles

https://www.nbcnews.com/health/health-news/us-prepares-possible-arrival-severe-strain-mpox-rcna169926 Senior Biden administrati...

Core News & Articles

https://ec.europa.eu/commission/presscorner/detail/en/ip_24_4523 Today, close to 100,000 mpox vaccine doses will arrive in the ...

 emergent-biosolutions-closed-a-new-credit-facility-agreement-with-oak-hill-advisors-for-a-term-loan-of-up-to-250m-and-repaid-senior-term-loan-facility-dated-october-15-2018-which-was-scheduled-to-mature-in-may-2025

The New Term Loan maturity extends up to five years, through August 2029. Excess proceeds from the refinancing will result in a...

 mpox-vaccine-emergent-biosolutions-smallpox-vaccine-gets-fda-nod-for-expanded-use-for-individuals-at-high-risk-of-mpox-infection

The FDA has approved Emergent BioSolutions' supplemental Biologics License Application for ACAM2000 to include the preventi...

 reported-earlier-emergent-biosolutions-acam2000-vaccine-gains-fda-nod-for-mpox-indication-amidst-rising-public-health-crisis

Emergent BioSolutions announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics Licens...

Core News & Articles

- Reuters

Core News & Articles

https://www.reviewjournal.com/life/health/mpox-case-reported-at-clark-county-detention-center-3148320/ One case of mpox has bee...

 who-seeks-135m-in-funding-to-fight-mpox-outbreak-can-be-controlled-and-can-be-stopped

To fight the mpox outbreak in Africa, the World Health Organization calls for funding help for its six-month plan.

Core News & Articles

https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-member-states-information-sessio...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION